Drugs for Head & Neck Cancer/Esophageal Cancer

Table. Drugs Prescribed for Head and Neck Cancer

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Erbitux (cetuximab)
Drug company
• Eli Lilly
Indication
• Treatment of advanced squamous-cell carcinoma of the head and neck, in combination with radiation therapy
  
  Recurrent locoregional or metastatic squamous-cell carcinoma of the head and neck, in combination with platinum-based chemotherapy with 5-fluorouracil
  
  Recurrent or metastatic squamous-cell carcinoma of the head and neck, progressing after platinum-based chemotherapy
Patient support services
• Lilly Oncology Infused Products Co‑pay Program
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• First-line treatment, in combination with chemotherapy, of metastatic or unresectable head and neck cancer
  
  First-line treatment, alone, of metastatic or unresectable, recurrent head and neck cancer with PD-L1 expression, as determined by an FDA-approved test
  
  Treatment of recurrent or metastatic head and neck cancer that progressed during or after platinum-containing chemotherapy
  
  Treatment of patients with locally advanced or metastatic esophageal carcinoma that cannot be removed by surgery or by chemoradiation, either in combination with chemotherapy or alone as a single agent, after 1 or more lines of therapy, in patients with squamous-cell tumor that expresses PD-L1, as determined by an FDA-approved test
Patient support services
• Merck Co‑pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment of recurrent or metastatic squamous-cell carcinoma of the head and neck
  
  Adjuvant treatment of completely resected esophageal cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy
  
  Treatment of unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma, after chemotherapy
  
  First-line treatment, in combination with fluoropyrimidine-and platinum-based chemotherapy, in patients with advanced or metastatic esophageal squamous-cell carcinoma
  
  First-line treatment, in combination with ipilimumab, in patients with advanced or metastatic esophageal squamous-cell carcinoma
Patient support services
• BMS Oncology Co‑pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003